PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT (Q2035314): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 50.00000049829505 percent) |
(Changed an Item) |
||||||
| Property / co-financing rate | |||||||
50.0 percent
| |||||||
| Property / co-financing rate: 50.0 percent / rank | |||||||
Normal rank | |||||||
Revision as of 04:31, 20 March 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT |
Project in Italy financed by DG Regio |
Statements
501,710.79 Euro
0 references
1,003,421.57 Euro
0 references
50.0 percent
0 references
13 December 2016
0 references
6 July 2019
0 references
CNR - CONSIGLIO NAZIONALE DELLE RICERCHE
0 references
MENARINI RICERCHE S.P.A.
0 references
41°40'3.11"N, 12°30'17.24"E
0 references
IL PROGETTO SI PROPONE LA CARATTERIZZAZIONE PRECLINICA DEL MEN1611, UN NUOVO INIBITORE DI PI3K CHE HA LA CAPACITÃ DI INIBIRE IN MODO PREFERENZIALE L?ISOFORMA ALFA, WILD TYPE E MUTATA. VERRANNO STUDIATI I DETERMINANTI MOLECOLARI DELLA SENSIBILITÃ (Italian)
0 references
Identifiers
F57H18000070007
0 references